https://oncbrain.oncologytoolkit.com/ AI-summarized oncology meeting studies, curated by a subspecialist. One item per study. en Sun, 31 May 2026 00:00:00 GMT https://oncbrain.oncologytoolkit.com/2026-05-31/#can-2409 https://oncbrain.oncologytoolkit.com/2026-05-31/#can-2409 Sun, 31 May 2026 00:00:00 GMT prostate [Confirmatory] DFS HR 0.70 (0.52-0.94), 2y biopsy persistence/recurrence 19.6% vs 36.4%, adding intraprostatic aglatimagene to EBRT in intermediate/high-risk localised prostate cancer. Eligible: Intermediate or high-risk localised prostate cancer, EBRT candidates, ECOG 0-2